Bevacizumab Linked to Greater ROP Retreatment than Ranibizumab
A real-world comparison of the anti-VEGF agents suggests certain doses are associated with more likelihood of retreatment.
Jennifer Lim, MD: Extended Durability in nAMD, DME Achieved with Faricimab
Faricimab treatment for both DME and nAMD was able to reliably get to 16 week dosing in 60% of eyes from YOSEMITE and RHINE and TENAYA and LUCERNE.
Proposed Aflibercept Biosimilar Provides Comparable Efficacy, Safety for DME
Findings from the INSIGHT study suggest MYL-1701P may provide a new anti-VEGF biosimilar option to patients with the common form of vision loss.
Faricimab Exhibits Durable Efficacy in nAMD Treatment in TENAYA and LUCERNE
The 48-week results suggest robust CST reduction and visual gains with faricimab up to every 16 week dosing, comparable with aflibercept ever 8-weeks.
Dilsher Dhoot, MD: Analysis of OTX-TKI Implant Shows Promise for Wet AMD Treatment
The data show 80% of patients were rescue-free up to 6 months with a single OTX-TKI implant injection.
Rishi Singh, MD: Efficacy of Pegcetacoplan for GA Based on 24-Month Data
A significant rate of reduction of geographic atrophy growth with pegcetacoplan was observed in both DERBY and OAKS over a 24-month period.
Charles Wykoff, MD, PhD: Shifting the Treatment Paradigm with Pegcetacoplan for GA
A look into major takeaways on efficacy, safety and functional data from the DERBY and OAKS trials on pegcetacoplan.
Peter J Kertes, MD: Insights into the TALON Trial on Brolucizumab Versus Aflibercept
Brolucizumab was deemed superior to aflibercept in treatment naive patients with neovascular age-related macular degeneration.
Initially Costlier, Ranibizumab PDS May Be More Cost-Effective Long-Term for nAMD Patients
New AAO 2022 data show the novel treatment administration may eventually save patients money versus standard anti-VEGF injfections.
EYP-1901 Safe, Tolerable for nAMD at 6 Months
New findings show the investigative single-dose agent is safe and associated with reduced rescue-dose anti-VEGF treatment.
Anti-VEGF Treatments Do Not Differ in Long-Term Intraocular Pressure
Comparison of 12- and 24-month regimens of common nAMD treatment show little difference in the common adverse event in patient eyes.
Two-Year Findings on Brolucizumab for nAMD Reported After MERLIN Trial Termination
Brolucizumab every four weeks met efficacy end points versus aflibercept at end of MERLIN study, but with higher incidences of intraocular inflammation.
Avacincaptad Pegol for GA Meets Primary Efficacy Endpoint in GATHER2 Trial
GATHER2 reports a 14.3% reduction in mean rate of growth in GA area over 12 months with avacincaptad pegol compared to sham.
Biosimilar SB15 Indicates Equivalent Efficacy to Aflibercept in nAMD Treatment
The least squares mean change from baseline in BCVA at Week 8 was 6.7 letters for SB15 versus 6.6 letters for aflibercept.
Theodore Leng, MD: Characterizing the Definition, Rates of Intermediate Dry AMD
Dr. Leng discusses the progression of dry AMD patients in the IRIS registry from early stages to potential GA, as well as the benefit in narrowing the clinical definition of intermediate dry AMD.
José-Alain Sahel, MD: Safety, Efficacy of Optogenetic Treatment for Retinitis Pigmentosa
At AAO 2021, Dr. Sahel discussed the findings of the PIONEER trial on the combination of an optogenetics device and gene therapy in treatment of RP.
Robert L. Avery, MD Highlights Results on RGX-314 For the Treatment Of Wet AMD
Dr. Avery discusses the positive results of RGX-314 gene therapy, noting dramatic reduction in need for therapy, with stable vision and good thickness results
Dilsher S. Dhoot, MD: Efficacy of Brolucizumab in Treatment of Diabetic Macular Edema
Dr. Dhoot discusses data on visual acuity from the phase 3 KESTREL and KITE trials, comparing brolucizumab to aflibercept at 52 weeks.
Arshad Khanani, MD Discusses Adverse Ocular Events After Brolucizumab Treatment
Dr. Khanani highlights data from MERLIN showing noninferiority of brolucizumab to aflibercept in nAMD treatment, but a higher rate of intraocular inflammation.
Veeral Sheth, MD: Identifying Durability, Safety of GB-102 in Wet AMD Treatment
Dr. Sheth discusses the data from the late-breaking Phase 2B ALTISSIMO study.
Carl D. Regillo, MD: Key Factors of Faricimab In Neovascular AMD Treatment
Dr. Regillo discusses the efficacy and durability of faricimab for wet AMD treatment in TENAYA and LUCERNE, showing noninferiority to aflibercept.
Rishi P. SIngh, MD: Advances and Challenges in Neovascular AMD Treatment
Dr. Singh discusses the aging population in ophthalmology care, advances including port delivery systems, and the potential rapid uptake of faricimab in treatment.
US Patient Access to Ophthalmology Clinical Trial Sites Differs by Regions
A geographical study shows patients in areas with lower income, education, and higher rates of ophthalmic disease may be a greater distance from a trial site.
Rishi P. SIngh, MD: Durability of Faricimab in Neovascular AMD Treatment
Dr. Singh discusses results from TENAYA and LUCERNE on faricimab compared to afilbercept in patients with nAMD.
Ranibizumab Biosimilar FYB201 Provides Similar Efficacy, Safety in Phase 3 Trial
The COLUMBUS-AMD trial suggests the investigative biosimilar could benefit patients newly diagnosed with nAMD.
New Model Could Predict Cost of PDR Prevention with Aflibercept
A cost-based assessment of Protocol W and PANORAMA clinical data suggests diabetic retinopathy may be less costly to prevent than macular edema.
Paul Sternberg, MD: Perspectives on Step Therapy in Wet AMD Treatment
Dr. Sternberg discusses step therapy in wetAMD treatment and his opinions in favor of its use.
Bevacizumab Formulation Significantly Improves wAMD Vision Versus Ranibizumab in NORSE 2
Bevacizumab-vikg was associated with statistically significant improvements in patient BCVA scores over a period of 12 months, according to phase 3 findings.
Treat-and-Extend for Anti-VEGF May Provide More Optimal Dosing and Fewer Clinic Visits
A meta-analysis comparison of dosing regimens for patients with nAMD show little difference in efficacy, but differences in patient involvement in care.
Vorolanib via Durasert Provides Safe Treatment of Wet AMD Through 12 Months
A phase 1 trial of the investigative drug suggests its promise in a novel strategy of managing patients with retinal fluid.
